Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Stroke Prevention Rehabilitation Intervention Trial of Exercise (SPRITE) - a randomised feasibility study.

Heron N, Kee F, Mant J, Reilly PM, Cupples M, Tully M, Donnelly M.

BMC Cardiovasc Disord. 2017 Dec 12;17(1):290. doi: 10.1186/s12872-017-0717-9.

2.

Infographics: Winning road cycle races: a Team Sky perspective.

Heron N, Usher R, MacLeod D, Sarrieguil I, Mercadel J, Tully MA.

Br J Sports Med. 2018 May;52(10):633-634. doi: 10.1136/bjsports-2017-097819. Epub 2017 Aug 10. No abstract available.

PMID:
28798038
3.

A comfort assessment of existing cervical orthoses.

Langley J, Pancani S, Kilner K, Reed H, Stanton A, Heron N, Judge S, McCarthy A, Baxter S, MazzĂ  C, McDermott CJ.

Ergonomics. 2018 Feb;61(2):329-338. doi: 10.1080/00140139.2017.1353137. Epub 2017 Jul 28.

PMID:
28697682
4.

Optimising secondary prevention in the acute period following a TIA of ischaemic origin.

Heron N.

BMJ Open Sport Exerc Med. 2017 Jan 6;2(1):e000161. doi: 10.1136/bmjsem-2016-000161. eCollection 2016. Review.

5.

Secondary prevention lifestyle interventions initiated within 90 days after TIA or 'minor' stroke: a systematic review and meta-analysis of rehabilitation programmes.

Heron N, Kee F, Cardwell C, Tully MA, Donnelly M, Cupples ME.

Br J Gen Pract. 2017 Jan;67(654):e57-e66. doi: 10.3399/bjgp16X688369. Epub 2016 Dec 5. Review.

6.

What to do after cardiac rehabilitation programs: the role of the general practitioner in cardiovascular prevention.

Cupples M, Heron N.

Monaldi Arch Chest Dis. 2016 Oct 14;86(1-2):755. doi: 10.4081/monaldi.2016.755.

7.

Behaviour change techniques in home-based cardiac rehabilitation: a systematic review.

Heron N, Kee F, Donnelly M, Cardwell C, Tully MA, Cupples ME.

Br J Gen Pract. 2016 Oct;66(651):e747-57. doi: 10.3399/bjgp16X686617. Epub 2016 Aug 1. Review.

8.

Evaluating a novel cervical orthosis, the Sheffield Support Snood, in patients with amyotrophic lateral sclerosis/motor neuron disease with neck weakness.

Baxter S, Reed H, Clarke Z, Judge S, Heron N, Mccarthy A, Langley J, Stanton A, Wells O, Squire G, Quinn A, Strong M, Shaw PJ, Mcdermott CJ.

Amyotroph Lateral Scler Frontotemporal Degener. 2016 Jul-Aug;17(5-6):436-42. doi: 10.3109/21678421.2016.1148170. Epub 2016 Feb 26.

PMID:
26915274
9.

Musculoskeletal (MSK) and Sport and Exercise Medicine (SEM) in General Practice (GP): A Novel GP-based MSK and SEM Clinic for Managing Musculoskeletal symptoms in a GP.

Heron N.

BMJ Qual Improv Rep. 2015 Feb 9;4(1). pii: u207172.w2905. doi: 10.1136/bmjquality.u207172.w2905. eCollection 2015.

10.

Assessment of the Sheffield Support Snood, an innovative cervical orthosis designed for people affected by neck muscle weakness.

Pancani S, Rowson J, Tindale W, Heron N, Langley J, McCarthy AD, Quinn A, Reed H, Stanton A, Shaw PJ, McDermott CJ, MazzĂ  C.

Clin Biomech (Bristol, Avon). 2016 Feb;32:201-6. doi: 10.1016/j.clinbiomech.2015.11.010. Epub 2015 Dec 2.

11.

Systematic review of the use of behaviour change techniques (BCTs) in home-based cardiac rehabilitation programmes for patients with cardiovascular disease--protocol.

Heron N, Kee F, Donnelly M, Tully MA, Cupples ME.

Syst Rev. 2015 Nov 17;4:164. doi: 10.1186/s13643-015-0149-5. Review.

12.

Head-Up; An interdisciplinary, participatory and co-design process informing the development of a novel head and neck support for people living with progressive neck muscle weakness.

Reed H, Langley J, Stanton A, Heron N, Clarke Z, Judge S, McCarthy A, Squire G, Quinn A, Wells O, Tindale W, Baxter S, Shaw PJ, McDermott CJ.

J Med Eng Technol. 2014;39(7):404-10. doi: 10.3109/03091902.2015.1088092.

PMID:
26453038
13.

Healthcare technology co-operatives: Innovative about innovation.

Heron NM, Tindale WB.

J Med Eng Technol. 2014;39(7):378-81. doi: 10.3109/03091902.2015.1087697.

PMID:
26453035
14.
15.

Systematic review of rehabilitation programmes initiated within 90 days of a transient ischaemic attack or 'minor' stroke: a protocol.

Heron N, Kee F, Donnelly M, Cupples ME.

BMJ Open. 2015 Jun 18;5(6):e007849. doi: 10.1136/bmjopen-2015-007849. Review.

16.

Correlates of sport participation in adults with long-standing illness or disability.

Heron N, Kee F, Cupples ME, Tully MA.

BMJ Open Sport Exerc Med. 2015 Jun 3;1(1):e000003. eCollection 2015.

17.

Femoral exostosis causing vastus medialis pain in an active young lady: a case report.

Heron N.

BMC Res Notes. 2015 Apr 2;8:119. doi: 10.1186/s13104-015-1077-0.

18.
19.

Physical activity assessment in practice: a mixed methods study of GPPAQ use in primary care.

Heron N, Tully MA, McKinley MC, Cupples ME.

BMC Fam Pract. 2014 Jan 15;15:11. doi: 10.1186/1471-2296-15-11.

20.

Development of two electronic bladder diaries: a patient and healthcare professionals pilot study.

Mangera A, Marzo A, Heron N, Fernando D, Hameed K, Soliman AH, Bradley M, Hosking I, Abdel-Maguid M, Levermore M, Tindale WB, Chapple C.

Neurourol Urodyn. 2014 Sep;33(7):1101-9. doi: 10.1002/nau.22469. Epub 2013 Sep 2.

PMID:
24000163
21.

International differences in sport medicine access and clinical management.

Heron N, Malliaropoulos NG.

Muscles Ligaments Tendons J. 2013 Jan 21;2(4):248-52. Print 2012 Oct.

22.

Steps to a better Belfast: physical activity assessment and promotion in primary care.

Heron N, Tully MA, McKinley MC, Cupples ME.

Br J Sports Med. 2014 Nov;48(21):1558-63. doi: 10.1136/bjsports-2012-091581. Epub 2013 Feb 12.

PMID:
23403530
23.

Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition.

Dossetter AG, Bowyer J, Cook CR, Crawford JJ, Finlayson JE, Heron NM, Heyes C, Highton AJ, Hudson JA, Jestel A, Krapp S, MacFaul PA, McGuire TM, Morley AD, Morris JJ, Page KM, Ribeiro LR, Sawney H, Steinbacher S, Smith C.

Bioorg Med Chem Lett. 2012 Sep 1;22(17):5563-8. doi: 10.1016/j.bmcl.2012.07.012. Epub 2012 Jul 15.

PMID:
22858142
24.

(1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritis.

Dossetter AG, Beeley H, Bowyer J, Cook CR, Crawford JJ, Finlayson JE, Heron NM, Heyes C, Highton AJ, Hudson JA, Jestel A, Kenny PW, Krapp S, Martin S, MacFaul PA, McGuire TM, Gutierrez PM, Morley AD, Morris JJ, Page KM, Ribeiro LR, Sawney H, Steinbacher S, Smith C, Vickers M.

J Med Chem. 2012 Jul 26;55(14):6363-74. doi: 10.1021/jm3007257. Epub 2012 Jul 10.

PMID:
22742641
25.

Trapezoid stress fracture in an international shot-putter: a case report.

Heron N, Verdugo F, Turmo A, Perez LT.

J Sports Sci Med. 2012 Dec 1;11(4):768-70. eCollection 2012.

26.

The influence of comorbidity on the risk of access-related bacteremia in chronic hemodialysis patients.

Mazonakis E, Stirling C, Booth KL, McClenahan J, Heron N, Geddes CC.

Hemodial Int. 2009 Jan;13(1):6-10. doi: 10.1111/j.1542-4758.2009.00327.x.

PMID:
19210271
27.

Synthesis and SAR of 1-acetanilide-4-aminopyrazole-substituted quinazolines: selective inhibitors of Aurora B kinase with potent anti-tumor activity.

Foote KM, Mortlock AA, Heron NM, Jung FH, Hill GB, Pasquet G, Brady MC, Green S, Heaton SP, Kearney S, Keen NJ, Odedra R, Wedge SR, Wilkinson RW.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):1904-9. doi: 10.1016/j.bmcl.2008.02.002. Epub 2008 Feb 7.

PMID:
18294849
28.

AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis.

Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, Foster JR, Brady MC, Bigley A, Brown E, Byth KF, Barrass NC, Mundt KE, Foote KM, Heron NM, Jung FH, Mortlock AA, Boyle FT, Green S.

Clin Cancer Res. 2007 Jun 15;13(12):3682-8.

29.

Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase.

Mortlock AA, Foote KM, Heron NM, Jung FH, Pasquet G, Lohmann JJ, Warin N, Renaud F, De Savi C, Roberts NJ, Johnson T, Dousson CB, Hill GB, Perkins D, Hatter G, Wilkinson RW, Wedge SR, Heaton SP, Odedra R, Keen NJ, Crafter C, Brown E, Thompson K, Brightwell S, Khatri L, Brady MC, Kearney S, McKillop D, Rhead S, Parry T, Green S.

J Med Chem. 2007 May 3;50(9):2213-24. Epub 2007 Mar 21.

PMID:
17373783
30.

Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors.

Jung FH, Pasquet G, Lambert-van der Brempt C, Lohmann JJ, Warin N, Renaud F, Germain H, De Savi C, Roberts N, Johnson T, Dousson C, Hill GB, Mortlock AA, Heron N, Wilkinson RW, Wedge SR, Heaton SP, Odedra R, Keen NJ, Green S, Brown E, Thompson K, Brightwell S.

J Med Chem. 2006 Feb 9;49(3):955-70.

PMID:
16451062
31.

SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors.

Heron NM, Anderson M, Blowers DP, Breed J, Eden JM, Green S, Hill GB, Johnson T, Jung FH, McMiken HH, Mortlock AA, Pannifer AD, Pauptit RA, Pink J, Roberts NJ, Rowsell S.

Bioorg Med Chem Lett. 2006 Mar 1;16(5):1320-3. Epub 2005 Dec 5.

PMID:
16337122
32.

Progress in the development of selective inhibitors of aurora kinases.

Mortlock AA, Keen NJ, Jung FH, Heron NM, Foote KM, Wilkinson RW, Green S.

Curr Top Med Chem. 2005;5(8):807-21. Review.

PMID:
16101420
33.

Progress in the development of selective inhibitors of Aurora kinases.

Mortlock A, Keen NJ, Jung FH, Heron NM, Foote KM, Wilkinson R, Green S.

Curr Top Med Chem. 2005;5(2):199-213. Review. Erratum in: Curr Top Med Chem. 2005;5(8):805. Corrected and republished in: Curr Top Med Chem. 2005;5(8):807-21.

PMID:
15853647
34.

Stereoselective Chelate-Controlled Addition of Grignard Reagents to Unsaturated Medium-Ring Heterocycles.

Adams JA, Heron NM, Koss AM, Hoveyda AH.

J Org Chem. 1999 Feb 5;64(3):854-860.

PMID:
11674157
35.

Primary human herpesvirus 7 infection: a comparison of human herpesvirus 7 and human herpesvirus 6 infections in children.

Caserta MT, Hall CB, Schnabel K, Long CE, D'Heron N.

J Pediatr. 1998 Sep;133(3):386-9.

PMID:
9738722
36.

Discovery of an orally bioavailable NK1 receptor antagonist, (2S,3S)-(2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine (GR203040), with potent antiemetic activity.

Ward P, Armour DR, Bays DE, Evans B, Giblin GM, Heron N, Hubbard T, Liang K, Middlemiss D, Mordaunt J, et al.

J Med Chem. 1995 Dec 22;38(26):4985-92.

PMID:
8544174
37.

Model for the cost analysis of shunted hydrocephalic children.

Cochrane D, Kestle J, Steinbok P, Evans D, Heron N.

Pediatr Neurosurg. 1995;23(1):14-9.

PMID:
7495661
38.

The role of attributions in the development of dating relationships.

Fletcher GJ, Fincham FD, Cramer L, Heron N.

J Pers Soc Psychol. 1987 Sep;53(3):481-9.

PMID:
3656081

Supplemental Content

Support Center